NCT07548450
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07548450
Title Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) (MPOWER)
Acronym MPOWER
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Utah
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.